In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:Strategies on how to approach different ARV-related toxicitiesOther factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)Clinically relevant drug–drug interactions related to HIV and gender-affirming careMethods to reduce barriers to ART adherenceFaculty: Jill Blumenthal, MD, MASAssociate Professor of MedicineInfectious Diseases and Global Public HealthUniversity of California, San DiegoSan Diego, CaliforniaJennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoPharmacistWomen’s HIV ProgramUniversity of California San Francisco Medical CenterSan Francisco, CaliforniaLink to full program:https://bit.ly/3PM3nYeFollow along with the slides at:https://bit.ly/3NpAYI1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related